AAV-vector-encoded ADCC-enhanced HER2-targeting antibody (Voyager Therapeutics)

N/A

Report date: 2026/01/26 17:58:55

Base Information

Drug NameAAV-vector-encoded ADCC-enhanced HER2-targeting antibody (Voyager Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsHuntington Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJapan National Institute of Neuroscience

China Registration ClassN/A

Develop Information

Active CompaniesJapan National Institute of Neuroscience

Inactive CompaniesN/A

Active IndicationsHuntington Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A